SI-BONE 경영진
경영진 기준 점검 2/4
SI-BONE CEO는 Laura Francis, Apr2021 에 임명되었습니다 의 임기는 5.08 년입니다. 총 연간 보상은 $7.45M, 9.2% 급여 및 90.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $7.13M 가치에 해당하는 회사 주식의 1.09% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.1 년과 15.4 년입니다.
핵심 정보
Laura Francis
최고경영자
US$7.5m
총 보수
| CEO 급여 비율 | 9.19% |
| CEO 재임 기간 | 5.1yrs |
| CEO 지분 보유율 | 1.1% |
| 경영진 평균 재임 기간 | 5.1yrs |
| 이사회 평균 재임 기간 | 15.4yrs |
최근 경영진 업데이트
Recent updates
분석 기사 • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...
내러티브 업데이트 • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).내러티브 업데이트 • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.내러티브 업데이트 • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).내러티브 업데이트 • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).내러티브 업데이트 • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.내러티브 업데이트 • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.내러티브 업데이트 • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.분석 기사 • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...분석 기사 • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...분석 기사 • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...분석 기사 • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...분석 기사 • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
새로운 내러티브 • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.분석 기사 • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...분석 기사 • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...분석 기사 • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...분석 기사 • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...분석 기사 • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$17m |
| Dec 31 2025 | US$7m | US$685k | -US$19m |
| Sep 30 2025 | n/a | n/a | -US$22m |
| Jun 30 2025 | n/a | n/a | -US$24m |
| Mar 31 2025 | n/a | n/a | -US$27m |
| Dec 31 2024 | US$7m | US$652k | -US$31m |
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$43m |
| Dec 31 2023 | US$4m | US$622k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$44m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$55m |
| Dec 31 2022 | US$5m | US$604k | -US$61m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$3m | US$527k | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$386k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$2m | US$375k | -US$38m |
보상 대 시장: Laura의 총 보수(USD7.45M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.71M)보다 높습니다.
보상과 수익: Laura의 보상은 회사가 적자임에도 증가했습니다.
CEO
Laura Francis (58 yo)
5.1yrs
재임 기간
US$7,453,235
보수
Ms. Laura A. Francis, MBA, has been an Independent Director of Bruker Corporation since February 18, 2025. She serves as Director at Galvanize Therapeutics, Inc. from November 2025. She serves as Chief Exe...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 18.1yrs | US$255.35k | 0.18% $ 1.2m | |
| CEO & Director | 5.1yrs | US$7.45m | 1.09% $ 7.1m | |
| COO & CFO | 5.1yrs | US$2.79m | 0.16% $ 1.0m | |
| Chief Business & Legal Affairs Officer | 9.8yrs | US$2.36m | 0.30% $ 2.0m | |
| Advisor | 9.8yrs | US$2.45m | 0.36% $ 2.4m | |
| Senior VP of Engineering & CTO | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of Financial Planning & Analysis and Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of Product & Marketing | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Clinical | 4.9yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer & VP of Medical Affairs | no data | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 5.1yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Market Access & Reimbursement | less than a year | 데이터 없음 | 데이터 없음 |
5.1yrs
평균 재임 기간
58yo
평균 나이
경험이 풍부한 관리: SIBN의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.1 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 18.1yrs | US$255.35k | 0.18% $ 1.2m | |
| CEO & Director | 5.1yrs | US$7.45m | 1.09% $ 7.1m | |
| Lead Independent Director | 18.1yrs | US$240.35k | 0.12% $ 774.0k | |
| Independent Director | 15.3yrs | US$217.60k | 0.39% $ 2.5m | |
| Independent Director | 6.4yrs | US$235.35k | 0.054% $ 357.5k | |
| Independent Director | 13.3yrs | US$215.35k | 0.28% $ 1.9m | |
| Member of Medical Advisory Board | 16.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | 16.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | 16.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | 15.4yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.2yrs | US$220.35k | 0.054% $ 356.1k | |
| Member of Surgeon Advisory Board | no data | 데이터 없음 | 데이터 없음 |
15.4yrs
평균 재임 기간
68yo
평균 나이
경험이 풍부한 이사회: SIBN의 이사회는 노련하고 경험이 풍부합니다(평균 재임 15.4 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 11:17 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
SI-BONE, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |